ZLDs Diabetic Nerve Pain Drug Trial Two-Thirds Enrolled
Filed with ASX · · 4 pages · English
Zelira Therapeutics Ltd. on 6ix
Earlier from Zelira Therapeutics
- Response to ASX Aware Query
- June 2022 Quarterly Activities Report
- Zenivol receives formal BfArM approval in Germany
- Response to ASX Price Query
- Pause in Trading
Later from Zelira Therapeutics
- September 2022 Quarterly Activities Report
- ZLD Completes Enrolment for Diabetic Nerve Pain Drug Trial
- Zelira receives $1.14 million cash R&D Tax Incentive
- December 2022 Quarterly Activities Report
- ZLD secures US$8.6 million funding for HOPE 1 US FDA trials
Follow Zelira Therapeutics into a list and get an email when it puts out news.
Follow Zelira Therapeutics